Entropy Technologies LP Makes New Investment in Guardant Health, Inc. (NASDAQ:GH)

Entropy Technologies LP purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 12,346 shares of the company’s stock, valued at approximately $377,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. JNBA Financial Advisors purchased a new stake in Guardant Health during the 3rd quarter worth approximately $26,000. R Squared Ltd acquired a new position in Guardant Health during the 4th quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new position in Guardant Health during the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC boosted its holdings in shares of Guardant Health by 168.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after buying an additional 2,153 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after buying an additional 796 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 2,652 shares of company stock worth $93,192. 5.50% of the stock is owned by company insiders.

Analyst Ratings Changes

GH has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partners reduced their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Sanford C. Bernstein cut their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Guggenheim restated a “buy” rating on shares of Guardant Health in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group upped their price objective on shares of Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Sixteen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $42.63.

Guardant Health Price Performance

Guardant Health stock opened at $45.38 on Thursday. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89. The stock has a market capitalization of $5.61 billion, a P/E ratio of -10.70 and a beta of 1.32. The firm’s 50-day moving average is $38.60 and its two-hundred day moving average is $30.91.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.